RxDoctor Payments Data

John Puleo, MD

Cardiovascular Disease · Sarasota, FLNPI 1649262882

Payments from drug & device makers

$4,486in general payments, 2019–2025

Across 202 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$487
  • Sanofi-aventis U.S. LLC$436
  • Pfizer$413
  • Philips North America LLC$390
  • Boston Scientific$356
  • Novartis$349
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,42799%
  • Education$581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,486 in reported general payments places this provider in the 55th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$502,797
Medicare patients
2,421
Services billed
7,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban377$392,136
XareltoRivaroxaban89$81,878
MultaqDronedarone Hcl24$32,410
EntrestoSacubitril/Valsartan21$16,499
Amiodarone Hcl66$5,546
Dabigatran EtexilateDabigatran Etexilate Mesylate17$3,568
Rosuvastatin Calcium211$2,521
Metoprolol Tartrate358$1,997
Metoprolol Succinate200$1,909
Diltiazem 12hr ErDiltiazem Hcl12$1,845
Atorvastatin Calcium261$1,784
ClopidogrelClopidogrel Bisulfate163$1,556
Losartan Potassium163$1,540
Valsartan37$1,322
Propafenone Hcl32$1,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$413$392,136377 claims
Johnson & JohnsonXarelto$29$81,87889 claims
Sanofi-aventis U.S. LLCMultaq$436$32,41024 claims
NovartisEntresto$349$16,49921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →